Full Text:   <1402>

Summary:  <391>

CLC number: R511

On-line Access: 2020-05-19

Received: 2020-02-29

Revision Accepted: 2020-03-09

Crosschecked: 2020-04-14

Cited: 0

Clicked: 2519

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Zhi Chen

https://orcid.org/0000-0002-0848-1502

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.5 P.343-360

http://doi.org/10.1631/jzus.B2000083


An overview of COVID-19


Author(s):  Yu Shi, Gang Wang, Xiao-peng Cai, Jing-wen Deng, Lin Zheng, Hai-hong Zhu, Min Zheng, Bo Yang, Zhi Chen

Affiliation(s):  State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more

Corresponding email(s):   minzheng@zju.edu.cn, yang924@zju.edu.cn, chenzhi@zju.edu.cn

Key Words:  Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pathogenesis, Epidemiology, Prevention and management


Share this article to: More |Next Article >>>

Yu Shi, Gang Wang, Xiao-peng Cai, Jing-wen Deng, Lin Zheng, Hai-hong Zhu, Min Zheng, Bo Yang, Zhi Chen. An overview of COVID-19[J]. Journal of Zhejiang University Science B, 2020, 21(5): 343-360.

@article{title="An overview of COVID-19",
author="Yu Shi, Gang Wang, Xiao-peng Cai, Jing-wen Deng, Lin Zheng, Hai-hong Zhu, Min Zheng, Bo Yang, Zhi Chen",
journal="Journal of Zhejiang University Science B",
volume="21",
number="5",
pages="343-360",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000083"
}

%0 Journal Article
%T An overview of COVID-19
%A Yu Shi
%A Gang Wang
%A Xiao-peng Cai
%A Jing-wen Deng
%A Lin Zheng
%A Hai-hong Zhu
%A Min Zheng
%A Bo Yang
%A Zhi Chen
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 5
%P 343-360
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000083

TY - JOUR
T1 - An overview of COVID-19
A1 - Yu Shi
A1 - Gang Wang
A1 - Xiao-peng Cai
A1 - Jing-wen Deng
A1 - Lin Zheng
A1 - Hai-hong Zhu
A1 - Min Zheng
A1 - Bo Yang
A1 - Zhi Chen
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 5
SP - 343
EP - 360
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000083


Abstract: 
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11, 2020, the World Health Organization (WHO) officially named the disease resulting from infection with SARS-CoV-2 as coronavirus disease 2019 (COVID-19). COVID-19 represents a spectrum of clinical manifestations that typically include fever, dry cough, and fatigue, often with pulmonary involvement. SARS-CoV-2 is highly contagious and most individuals within the population at large are susceptible to infection. Wild animal hosts and infected patients are currently the main sources of disease which is transmitted via respiratory droplets and direct contact. Since the outbreak, the Chinese government and scientific community have acted rapidly to identify the causative agent and promptly shared the viral gene sequence, and have carried out measures to contain the epidemic. Meanwhile, recent research has revealed critical aspects of SARS-CoV-2 biology and disease pathogenesis; other studies have focused on epidemiology, clinical features, diagnosis, management, as well as drug and vaccine development. This review aims to summarize the latest research findings and to provide expert consensus. We will also share ongoing efforts and experience in China, which may provide insight on how to contain the epidemic and improve our understanding of this emerging infectious disease, together with updated guidance for prevention, control, and critical management of this pandemic.

2019冠状病毒病(COVID-19)概览

概要:2019年12月中国湖北省武汉市爆发由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染引起的新型冠状病毒肺炎.2020年2月11日,世界卫生组织(World Health Organization,WHO)将该疾病正式命名为COVID-19(coronavirus disease 2019).COVID-19临床表现多样,典型表现为发热、干咳和乏力,常出现肺部受累.SARS-CoV-2传染性较强,人群普遍易感.野生动物宿主和患者为SARS-CoV-2主要传染源,呼吸道飞沫传播和接触传播为主要传播途径.自发现该病流行以来,中国政府和科学界迅速明确了此次疫情病原体,并及时向全世界公开病毒基因序列,同时采取一系列措施控制疫情.全球科研工作者从新型冠状病毒肺炎的病原生物学和发病机制、流行病学、临床特征、诊断治疗和药物疫苗研发等各方面入手,开展了一系列研究工作.本文通过综述最新研究成果、专家共识,以及中国抗疫经验,以期加强对该新发传染病的认识,为防控治疗提供参考.
关键词:2019冠状病毒病(COVID-19);严重急性呼吸综合征冠状病毒2(SARS-CoV-2);发病机理;流行病学;预防及治疗

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Agostini ML, Andres EL, Sims AC, et al., 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9(2):e00221-18.

[2]Al-Tawfiq JA, Alfaraj SH, Altuwaijri TA, et al., 2017. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J Infect, 75(4):378-379.

[3]Arabi Y, Balkhy H, Hajeer AH, et al., 2015. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 4:709.

[4]Asselah T, Benhamou Y, Marcellin P, 2009. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int, 29(S1):57-67.

[5]Badgett MR, Auer A, Carmichael LE, et al., 2002. Evolutionary dynamics of viral attenuation. J Virol, 76(20):10524-10529.

[6]Bao YP, Sun YK, Meng SQ, et al., 2020. 2019-nCoV epidemic: address mental health care to empower society. Lancet, 395(10224):E37-E38.

[7]Brown AJ, Won JJ, Graham RL, et al., 2019. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res, 169:104541.

[8]Ceraolo C, Giorgi FM, 2020. Genomic variance of the 2019-nCoV coronavirus. J Med Virol, 92(5):522-528.

[9]Chan JFW, Yuan SF, Kok KH, et al., 2020a. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395(10223):514-523.

[10]Chan JFW, Kok KH, Zhu Z, et al., 2020b. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 9(1):221-236.

[11]Chen HJ, Guo JJ, Wang C, et al., 2020. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet, 395(10226):809-815.

[12]Chen LJ, Liu WY, Zhang Q, et al., 2020. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect, 9(1):313-319.

[13]Chen NS, Zhou M, Dong X, et al., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223):507-513.

[14]Chu CM, Cheng VCC, Hung IFN, et al., 2004. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59(3):252-256.

[15]Cui HZ, Gao ZY, Liu M, et al., 2020. Structural genomics and interactomics of 2019 Wuhan novel coronavirus, 2019-nCoV, indicate evolutionary conserved functional regions of viral proteins. bioRxiv, preprint.

[16]Cui QH, Huang CB, Ji XW, et al., 2020. Possible inhibitors of ACE2, the receptor of 2019-nCoV. Preprints, 2020020047.

[17]https://doi.org/10.20944/Preprints202002.0047.V1

[18]Cyranoski D, 2020. When will the coronavirus outbreak peak? Nature, Feb. 18, 2020.

[19]de Wit E, van Doremalen N, Falzarano D, et al., 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 14(8):523-534.

[20]Dong N, Yang XM, Ye LM, et al., 2020. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv, preprint.

[21]Drosten C, Günther S, Preiser W, et al., 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 348(20):1967-1976.

[22]Fan W, Yang C, Cui M, 2020. The first doctor to report the epidemic: “I realized that something was wrong and I started to prepare.” people.cn. http://society.people.com.cn/n1/2020/0207/c1008-31575058.html [Accessed on Feb. 28, 2020] (in Chinese).

[23]Fang Q, 2020. Nan-shan ZHONG’s team isolated neocoronavirus from a patient’s urine specimen. Guangzhou Daily. https://gzdaily.dayoo.com/pc/html/2020-02/23/content_127574_683801.htm [Accessed on Feb. 28, 2020] (in Chinese).

[24]Favre G, Pomar L, Musso D, et al., 2020. 2019-nCoV epidemic: what about pregnancies? Lancet, 389(10224):E40.

[25]Gallagher TM, Buchmeier MJ, 2001. Coronavirus spike proteins in viral entry and pathogenesis. Virology, 279(2):371-374.

[26]Gao S, Song SQ, Zhang LL, 2019. Recent progress in vaccine development against chikungunya virus. Front Microbiol, 10:2881.

[27]General Office of National Health Commission of the People’s Republic of China, 2020. Diagnosis and treatment for novel coronavirus (Version 5). http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml [Accessed on Feb. 28, 2020] (in Chinese).

[28]Guan WJ, Ni ZY, Hu Y, et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, in press.

[29]Guo Q, Li M, Wang CH, et al., 2020. Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm. bioRxiv, preprint.

[30]He YX, Jiang SB, 2005. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol, 18(2):327-332.

[31]Heurich A, Hofmann-Winkler H, Gierer S, et al., 2014. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol, 88(2):1293-1307.

[32]Hoffmann M, Kleine-Weber H, Krüger N, et al., 2020. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, preprint.

[33]Hofmann H, Pöhlmann S, 2004. Cellular entry of the SARS coronavirus. Trends Microbiol, 12(10):466-472.

[34]Huang CL, Wang YM, Li XW, et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223):497-506.

[35]Huang Q, Herrmann A, 2020. Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). bioRxiv, preprint.

[36]Jaimes JA, André NM, Millet JK, et al., 2020. Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses. bioRxiv, preprint.

[37]Ji W, Wang W, Zhao XF, et al., 2020. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol, 92(4):433-440.

[38]Jiang SB, Shi ZL, 2020. The first disease X is caused by a highly transmissible acute respiratory syndrome coronavirus. Virol Sin, in press.

[39]Jin YH, Cai L, Cheng ZS, et al., 2020. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res, 7(1):4.

[40]King AMQ, Adams MJ, Carstens EB, et al., 2012. Virus Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier, San Diego, USA, p.770-783.

[41]Kong LH, 2020. South China Agricultural University: pangolin maybe the intermediate host for new coronavirus. people.cn. http://bj.people.com.cn/n2/2020/0208/c14540-33775751.html [Accessed on Feb. 28, 2020] (in Chinese).

[42]Ksiazek TG, Erdman D, Goldsmith CS, et al., 2003. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med, 348(20):1953-1966.

[43]Lam TTY, Shum MHH, Zhu HC, et al., 2020. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature, in press.

[44]Lan J, Ge JW, Yu JF, et al., 2020. Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv, preprint.

[45]Lefkowitz EJ, Dempsey DM, Hendrickson RC, et al., 2018. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res, 46(D1):D708-D717.

[46]Leonard JN, Schaffer DV, 2006. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther, 13(6):532-540.

[47]Li CKF, Xu XN, 2010. Host immune responses to SARS coronavirus in humans. In: Lal SK (Ed.), Molecular Biology of the SARS-Coronavirus. Springer, Berlin, Heidelberg, p.259-278.

[48]Li F, 2016. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol, 3(1):237-261.

[49]Li F, Li WH, Farzan M, et al., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science, 309(5742):1864-1868.

[50]Li GD, de Clercq E, 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Dis, 19(3):149-150.

[51]Li Q, Guan XH, Wu P, et al., 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 382(13):1199-1207.

[52]Liu P, Chen W, Chen JP, 2019. Viral metagenomics revealed Sendai virus and coronavirus infection of Malayan Pangolins (Manis javanica). Viruses, 11(11):979.

[53]Lou ZY, Sun Y, Rao ZH, 2014. Current progress in antiviral strategies. Trends Pharmacol Sci, 35(2):86-102.

[54]Loutfy MR, Blatt LM, Siminovitch KA, et al., 2003. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA, 290(24):3222-3228.

[55]Lu RJ, Zhao X, Li J, et al., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395(10224):565-574.

[56]Meng T, Cao H, Zhang H, et al., 2020. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS. bioRxiv, preprint.

[57]Millet JK, Whittaker GR, 2015. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res, 202:120-134.

[58]Mulangu S, Davey RT Jr, Mbaya OT, et al., 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med, 381(24):2293-2303.

[59]Munster VJ, Koopmans M, van Doremalen N, et al., 2020. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med, 382(8):692-694.

[60]Patick AK, Potts KE, 1998. Protease inhibitors as antiviral agents. Clin Microbiol Rev, 11(4):614-627.

[61]Plotkin SA, 2005. Vaccines: past, present and future. Nat Med, 11(4):S5-S11.

[62]Razzaque MS, Taguchi T, 2003. Pulmonary fibrosis: cellular and molecular events. Pathol Int, 53(3):133-145.

[63]Rothe C, Schunk M, Sothmann P, et al., 2020. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New Engl J Med, 382(10):970-971.

[64]Sheahan TP, Sims AC, Leist SR, et al., 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 11:222.

[65]Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association, 2020. An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19). Chin J Epidemiol, 41(2):139-144 (in Chinese).

[66]Stauffer F, El-Bacha T, da Poian AT, 2006. Advances in the development of inactivated virus vaccines. Recent Pat Anti-Infect Drug Discov, 1(3):291-296.

[67]ter Meulen J, van den Brink EN, Poon LLM, et al., 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med, 3(7):e237.

[68]Walls AC, Park YJ, Tortorici MA, et al., 2020. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 180:281-292.

[69]Wang DW, Hu B, Hu C, et al., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11):1061-1069.

[70]Wang M, Cao R, Zhang L, et al., 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 30(3):269-271.

[71]Watts JK, Corey DR, 2012. Silencing disease genes in the laboratory and the clinic. J Pathol, 226(2):365-379.

[72]Wax RS, Christian MD, 2020. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anesth/J Can Anesth, 67:568-576.

[73]World Health Organization, 2020. Coronavirus disease 2019 (COVID-19). Situation Report-55. World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports [Accessed on Mar. 16, 2020].

[74]Wrapp D, Wang N, Corbett KS, et al., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483):1260-1263.

[75]Wu F, Zhao S, Yu B, et al., 2020. A new coronavirus associated with human respiratory disease in China. Nature, 579(7798):265-269.

[76]Xie CB, Jiang LX, Huang G, et al., 2020. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis, 93:264-267.

[77]Xinhuanet, 2020. Nan-shan ZHONG’s and Lan-juan LI’s teams isolated the virus from the stools of patients with new coronary pneumonia. Xinhuanet. http://m.xinhuanet.com/hb/2020-02/13/c_1125570909.htm [Accessed on Feb. 28, 2020] (in Chinese).

[78]Xu KJ, Cai HL, Shen YH, et al., 2020. Management of corona virus disease-19 (COVID-19):the Zhejiang experience. J Zhejiang Univ (Med Sci) (in Chinese).

[79]Xu XT, Chen P, Wang JF, et al., 2020. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 63(3):457-460.

[80]Xu XW, Wu XX, Jiang XG, et al., 2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ, 368:m606.

[81]Xu Z, Shi L, Wang YJ, et al., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8:420-422.

[82]Yan RH, Zhang YY, Li YN, et al., 2020. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science, 367(6485):1444-1448.

[83]Yang XB, Yu Y, Xu JQ, et al., 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 8(4):e26.

[84]Yang Y, Lu QB, Liu MJ, et al., 2020. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv, preprint.

[85]Young BE, Ong SWX, Kalimuddin S, et al., 2020. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA, 323(15):1488-1494.

[86]Zaki AM, van Boheemen S, Bestebroer TM, et al., 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 367(19):1814-1820.

[87]Zhang NR, Jiang SB, Du LY, 2014. Current advancements and potential strategies in the development of MERS-CoV vaccines. Exp Rev Vaccin, 13(6):761-774.

[88]Zhang T, Wu QF, Zhang ZG, 2020. Pangolin homology associated with 2019-nCoV. bioRxiv, preprint.

[89]Zhao HJ, Zhou J, Zhang K, et al., 2016. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep, 6:22008.

[90]Zhao JC, Perera RAPM, Kayali G, et al., 2015. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol, 89(11):6117-6120.

[91]Zhao ZQ, Lv Q, 2020. How is the progress of new coronary pneumonia drugs and vaccines? The scientist came to answer the question. people.cn. http://scitech.people.com.cn/n1/2020/0215/c1007-31588725.html [Accessed on Feb. 28, 2020] (in Chinese).

[92]Zheng QL, Duan T, Jin LP, 2020. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal-fetal interface. Reprod Dev Med, 4(1):7-10.

[93]Zhou P, Yang XL, Wang XG, et al., 2020a. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv, preprint.

[94]Zhou P, Yang XL, Wang XG, et al., 2020b. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798):270-273.

[95]Zhou YY, Zeng YY, Tong YQ, et al., 2020. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. medRxiv, preprint.

[96]Zhu N, Zhang DY, Wang WL, et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382(8):727-733.

[97]Zou LR, Ruan F, Huang MX, et al., 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med, 382(12):1177-1179.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE